Molecular Partners Presents Positive Imaging and Dosimetry Data for DLL3-Targeting Radiotherapy MP0712 at TWC 2026

Molecular Partners announced the presentation of first imaging and dosimetry data for MP0712, its DLL3-targeting Radio-DARPin candidate, at the Theranostics World Congress 2026. The data showed specific tumor accumulation and attractive biodistribution, supporting clinical development for treatment of DLL3-expressing cancers. Dosimetry data highlighted Radio-DARPins as a vector for precise delivery of potent alpha-emitting isotopes to tumors. The MP0712 Phase 1/2a study is open in the US, with initial clinical data expected in 2026.